Beyond Air reported fiscal 2026 revenue surged 107% year-on-year to $7.7 million and swung to $2 million gross profit from a $1.7 million loss. Net loss narrowed to $33.2 million ($4.01/share) as cash burn fell 56% to $19.1 million, with $17.3 million in cash and equivalents and debt of $21.6 million.
Beyond Air’s fiscal 2026 revenue climbed 107% to $7.7 million, driven by strong demand for its LungFit PH system. Gross profit improved by $300,000, reversing a prior-year loss of $1.7 million to $2 million in profitability.
Research and development expenses fell 39% to $10.2 million and SG&A expenses declined 27% to $19.1 million. Net cash burn dropped 56% to $19.1 million, leaving $17.3 million in cash and equivalents as of March 31, 2026.
Total long-term debt stands at $21.6 million, which may constrain financial flexibility. The company faces Nasdaq listing compliance issues and plans a reverse stock split to meet minimum bid price requirements.
Beyond Air holds regulatory clearances in over 45 countries and secured national purchasing agreements with major US group purchasing organizations. Management reports the second-generation LungFit PH PMA supplement is on track, with tests completed and FDA audits anticipated in coming months.
